Medicare Spending on New Alzheimer’s Drugs Is Lower Than Expected

A few years ago, government officials in the United States expected to spend billions of dollars every year on new Alzheimer’s medications. However, a new report from STAT News shows that the reality is very different. Medicare, the federal health insurance program for people aged 65 and older, is now spending much less than expected on these new drugs. In fact, officials do not expect to see large spending on these treatments in 2026 or 2027. This is a major change from the high costs that experts once predicted for medicines like Leqembi and Kisunla.

According to STAT News, the number of patients using these drugs is much lower than the government first thought. When these medications were first approved, there was a lot of excitement about their potential to help people with Alzheimer’s disease. However, the actual use of these drugs has been very quiet. A spokesperson for the Centers for Medicare and Medicaid Services told STAT that the agency is no longer forecasting significant spending on these treatments. This shift highlights the many difficulties that have appeared since the drugs were first released to the public.

Neurologists and experts in Medicare programs explained to STAT that there are several reasons why fewer people are using these treatments. First, the drugs are intravenous, meaning they must be given to the patient through a needle in the arm. This process is not easy to manage for many patients. Furthermore, the treatment requires a lot of imaging, such as brain scans, to make sure the patient is responding well. These extra steps make it harder for doctors to provide the care and for patients to receive it. Because of these requirements, the number of patients who are actually able to use these drugs is quite limited.

Beyond the difficulty of giving the medicine, there are also serious concerns about health risks. Medical experts told STAT that these drugs continue to show only small benefits for patients. At the same time, the medications carry a risk of severe side effects, including the possibility of brain bleeding. These risks make both doctors and patients more careful about choosing this path of treatment. When the potential for harm is high and the clear benefits are small, many people decide that the treatment is not the right choice for them.

This situation is very different from the predictions made just two years ago. At that time, many people thought that Leqembi alone would cost the Medicare system billions of dollars every year. The fact that spending has stayed so low shows how quickly expectations can change when a new drug meets the reality of medical practice. While these drugs represent a new area of science for Alzheimer’s, the practical challenges of using them have kept them from becoming a common treatment for most patients.

In the broader world of medicine, these challenges are not unique to Alzheimer’s drugs. For example, STAT News also reported on other issues in the healthcare system, such as shortages of estrogen patches. While the U.S. Food and Drug Administration has not officially listed these patches as being in short supply, other groups like the American Society of Health-System Pharmacists have identified many brands and dosages that are hard to find. This shows that the healthcare system often faces complex problems, whether it is the low use of expensive new drugs or the lack of supply for common treatments.

Looking ahead, it is clear that the future of Alzheimer’s treatment will depend on more than just the approval of new drugs. It will depend on how easy these drugs are to use, how safe they are, and whether they provide real, meaningful help to patients. For now, the lower-than-expected spending suggests that the medical community is taking a cautious approach. As more data becomes available, doctors and officials will continue to watch these trends to see if the situation changes. For the millions of people affected by Alzheimer’s, the search for effective and safe treatments remains a very important goal, even if the current path is more difficult than many had hoped.